- Home
- ADXN vs VYNE Comparison
ADXN vs VYNE Comparison
Compare ADXN & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- VYNE
- Stock Information
- Founded
- ADXN 2002
- VYNE 2003
- Country
- ADXN Switzerland
- VYNE United States
- Employees
- ADXN N/A
- VYNE N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- VYNE Health Care
- Exchange
- ADXN Nasdaq
- VYNE Nasdaq
- Market Cap
- ADXN 8.5M
- VYNE 9.6M
- IPO Year
- ADXN N/A
- VYNE 2018
- Fundamental
- Price
- ADXN $8.86
- VYNE $0.35
- Analyst Decision
- ADXN
- VYNE Buy
- Analyst Count
- ADXN 0
- VYNE 2
- Target Price
- ADXN N/A
- VYNE $8.00
- AVG Volume (30 Days)
- ADXN 23.3K
- VYNE 3.1M
- Earning Date
- ADXN 11-21-2025
- VYNE 11-06-2025
- Dividend Yield
- ADXN N/A
- VYNE N/A
- EPS Growth
- ADXN N/A
- VYNE N/A
- EPS
- ADXN N/A
- VYNE N/A
- Revenue
- ADXN $210,347.00
- VYNE $476,000.00
- Revenue This Year
- ADXN $86.57
- VYNE N/A
- Revenue Next Year
- ADXN N/A
- VYNE N/A
- P/E Ratio
- ADXN N/A
- VYNE N/A
- Revenue Growth
- ADXN N/A
- VYNE N/A
- 52 Week Low
- ADXN $6.51
- VYNE $0.28
- 52 Week High
- ADXN $12.05
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- ADXN 48.84
- VYNE 46.25
- Support Level
- ADXN $8.53
- VYNE $0.34
- Resistance Level
- ADXN $10.55
- VYNE $0.39
- Average True Range (ATR)
- ADXN 0.72
- VYNE 0.04
- MACD
- ADXN -0.03
- VYNE 0.00
- Stochastic Oscillator
- ADXN 9.86
- VYNE 17.15
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.